Targeting the skeletal muscle-metabolism axis in prostate-cancer therapy

New England Journal of Medicine

Volumn 367, Issue 10, 2012, Pages 965-967

  Basaria, Shehzad ^a   Bhasin, Shalender ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; CYTOKINE; FOLLISTATIN; GROWTH HORMONE SECRETAGOGUE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MYOSTATIN; MYOSTATIN MONOCLONAL ANTIBODY; PROTEIN AKT1; PROTEIN KINASE B; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG TARGETING; FRACTURE; HUMAN; INFLAMMATION; MALE SEXUAL DYSFUNCTION; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE HYPOTONIA; MUSCLE METABOLISM; MUSCLE WEAKNESS; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 84865690478     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1203160     Document Type: Article

References (11)

1. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006;106:581-8. (Pubitemid 43157621)
2. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042-9. (Pubitemid 351831513)
3. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56. (Pubitemid 46630983)
4. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500. (Pubitemid 47463063)
5. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004;53:1643-8. (Pubitemid 38864744)
6. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90. (Pubitemid 27202654)
7. Tu P, Bhasin S, Hruz PW, et al. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes 2009;58:1739-48.
8. Izumiya Y, Hopkins T, Morris C, et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008;7:159-72. (Pubitemid 351168553)
9. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007;2(8):e789.
10. Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 2012;55:183-93.
11. Boström P, Wu J, Jedrychowski MP, et al. PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-8.